Spruce Biosciences (SPRB) Non-Current Assets (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Non-Current Assets of $1.1 million for Q1 2026, up 5.68% year-over-year from $1.1 million in Q1 2025, and up 24.75% quarter-over-quarter from $909000.0 in Q4 2025.
Spruce Biosciences (SPRB) Non-Current Assets (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Non-Current Assets for 8 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 5.68% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $3.7 million (down 28.88% YoY), while the FY2025 annual figure was $909000.0, down 9.37% from the prior year.
- Non-Current Assets rose to $1.1 million in Q1 2026 per SPRB's latest filing, from $909000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $19.9 million in Q1 2022 and bottomed at $797000.0 in Q3 2025.
- Historically, Non-Current Assets has averaged $2.9 million across 5 years, with a median of $1.7 million in 2024.
- On a YoY basis, Non-Current Assets climbed as much as 727.11% in 2022 and fell as far as 94.87% in 2022.
- Spruce Biosciences' Non-Current Assets stood at $2.0 million in 2022, then fell by 13.58% to $1.8 million in 2023, then tumbled by 43.11% to $1.0 million in 2024, then dropped by 9.37% to $909000.0 in 2025, then rose by 24.75% to $1.1 million in 2026.
- Business Quant data shows SPRB's Non-Current Assets at $1.1 million in Q1 2026, $909000.0 in Q4 2025, and $797000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | 1.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.70 Mn |
| Mar 31, 2026 | 1.13 Mn |
| Dec 31, 2025 | 909,000.00 |
| Sep 30, 2025 | 797,000.00 |
| Jun 30, 2025 | 867,000.00 |
| Mar 31, 2025 | 1.07 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 1.67 Mn |
| Dec 31, 2023 | 1.76 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Jun 30, 2023 | 1.83 Mn |
| Mar 31, 2023 | 1.88 Mn |
| Dec 31, 2022 | 2.04 Mn |
| Sep 30, 2022 | 2.11 Mn |
| Jun 30, 2022 | 8.01 Mn |
| Mar 31, 2022 | 19.89 Mn |
| Dec 31, 2021 | 34.59 Mn |
| Sep 30, 2021 | 41.17 Mn |